Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ibio Inc (IBIO)

Ibio Inc (IBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
iBio to Participate in the 8th Annual Evercore Healthcare Conference

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the 8th Annual Evercore...

IBIO : 1.2000 (-6.25%)
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Strengthened cash position and extended runway  into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds ...

IBIO : 1.2000 (-6.25%)
iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment discontinuation...

IBIO : 1.2000 (-6.25%)
Why Armata Pharmaceuticals Skyrocketed 370% Today

Armata Pharmaceuticals (NYSE American: ARMP) surprised Wall Street on Wednesday after its stock rocketed as much as 370% intraday on the back of groundbreaking mid-stage clinical results for its bacteriophage-based...

ESLA : 1.9900 (+3.11%)
SLP : 19.64 (-4.15%)
ARMP : 5.63 (-5.22%)
BNBX : 3.00 (-3.23%)
IBIO : 1.2000 (-6.25%)
iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and...

IBIO : 1.2000 (-6.25%)
iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June...

IBIO : 1.2000 (-6.25%)
iBio Announces Closing of $50 Million Public Offering

Total gross proceeds of $100 million if all Series G warrants and Series H warrants are exercised for cash Financing was led by Balyasny Asset Management and included participation from Cormorant...

IBIO : 1.2000 (-6.25%)
iBio Announces Pricing of $50 Million Public Offering

SAN DIEGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc.  (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the pricing of an underwritten public offering (the...

IBIO : 1.2000 (-6.25%)
iBio Announces Proposed Public Offering

SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc.  (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced it has commenced an underwritten public offering (the...

IBIO : 1.2000 (-6.25%)
iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

IBIO : 1.2000 (-6.25%)

Barchart Exclusives

As Nike Shakes Up Its C-Suite, Should You Buy, Sell, or Hold NKE Stock?
Nike’s sweeping C-suite overhaul under its “Win Now” plan signals a bold reset. So, is the stock a buy, sell, or hold? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar